1. Cameron J.S.. Nephrotic syndrome in the elderly.
Semin Nephrol 16:1996;319–329.
2. Zech P., Colon S., Pointet P., Deteix P., Labeeuw M., Leitienne P.. The nephrotic syndrome in adults aged over 60: etiology, evolution and treatment of 76 cases.
Clin Nephrol 17:1982;232–236.
3. Chang J.H., Kim D.K., Kim H.W., Park S.Y., Yoo T.H., Kim B.S., Kang S.W., Choi K.H., Han D.S., Jeong H.J., Lee H.Y.. Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience.
Nephrol Dial Transplant 24:2009;2406–2410.
4. Tune B.M., Mendoza S.A.. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.
J Am Soc Nephrol 8:1997;824–832.
5.
6. Palmer S.C., Nand K., Strippoli G.F.. Interventions for minimal change disease in adults with nephrotic syndrome.
Cochrane Database Syst Rev 2008 CD001537.
7. Waldman M., Crew R.J., Valeri A., Busch J., Stokes B., Markowitz G., D'Agati V., Appel G.. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
Clin J Am Soc Nephrol 2:2007;445–453.
8. Li X., Li H., Chen J., He Q., Lv R., Lin W., Li Q., He X., Qu L., Suya W.. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
Nephrol Dial Transplant 23:2008;1919–1925.
9. Inoue Y., Iijima K., Nakamura H., Yoshikawa N.. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome.
Pediatr Nephrol 13:1999;33–38.
10. Prasad N., Gulati S., Sharma R.K., Singh U., Ahmed M.. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.
Pediatr Nephrol 19:2004;494–498.
11. Ponticelli C., Edefonti A., Ghio L., Rizzoni G., Rinaldi S., Gusmano R., Lama G., Zacchello G., Confalonieri R., Altieri P.. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial.
Nephrol Dial Transplant 8:1993;1326–1332.
12. Latta K., von Schnakenburg C., Ehrich J.H.. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children.
Pediatr Nephrol 16:2001;271–282.
13. Falkiewicz K., Kaminska D., Nahaczewska W., Boratynska M., Owczarek H., Klinger M., Wozniak M., Patrzalek D., Szyber P.. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation.
Transplant Proc 38:2006;119–122.
14. Denton M.D., Magee C.C., Sayegh M.H.. Immunosuppressive strategies in transplantation.
Lancet 353:1999;1083–1091.
15. Schweda F., Liebl R., Riegger G.A., Krämer B.K.. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome.
Nephrol Dial Transplant 12:1997;2433–2435.
16. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., Kusek J.W., Van Lente F.. Chronic Kidney Disease Epidemiology Collaboration: using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Ann Intern Med 145:2006;247–254.
17. Huang J.J., Hsu S.C., Chen F.F., Sung J.M., Tseng C.C., Wang M.C.. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis.
Am J Nephrol 21:2001;28–34.
18. Nakayama M., Katafuchi R., Yanase T., Ikeda K., Tanaka H., Fujimi S.. Steroid responsiveness and frequency of relapse in adult (–) onset minimal change nephrotic syndrome.
Am J Kidney Dis 39:2002;503–512.
19. J Pediatr.
20. J Pediatr.
21. rd.
22. Gummert J.F., Ikonen T., Morris R.E.. Newer immunosuppressive drugs: a review.
J Am Soc Nephrol 10:1999;1366–1380.
23. Sasakawa Y., Sakuma S., Higashi Y., Sasakawa T., Amaya T., Goto T.. FK506 suppresses neutrophil chemoattractant production by peripheral blood mononuclear cells.
Eur J Pharmacol 403:2000;281–288.
24. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., Chang J.M., Choi H.Y., Campbell K.N., Kim K., Reiser J., Mundel P.. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.
Nat Med 14:2008;931–938.